WO2005082892A3 - Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant - Google Patents

Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant Download PDF

Info

Publication number
WO2005082892A3
WO2005082892A3 PCT/IB2005/000343 IB2005000343W WO2005082892A3 WO 2005082892 A3 WO2005082892 A3 WO 2005082892A3 IB 2005000343 W IB2005000343 W IB 2005000343W WO 2005082892 A3 WO2005082892 A3 WO 2005082892A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions containing
triazole compounds
antibacterial agents
compounds
Prior art date
Application number
PCT/IB2005/000343
Other languages
English (en)
Other versions
WO2005082892A2 (fr
Inventor
Jagattaran Das
Mohamed Takhi
Selvakumar Natesan
Sanjay Trehan
Javed Iqbal
Sitaram Kumar Magadi
Sreenivas Kandepu
Original Assignee
Reddys Lab Ltd Dr
Jagattaran Das
Mohamed Takhi
Selvakumar Natesan
Sanjay Trehan
Javed Iqbal
Sitaram Kumar Magadi
Sreenivas Kandepu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Jagattaran Das, Mohamed Takhi, Selvakumar Natesan, Sanjay Trehan, Javed Iqbal, Sitaram Kumar Magadi, Sreenivas Kandepu filed Critical Reddys Lab Ltd Dr
Publication of WO2005082892A2 publication Critical patent/WO2005082892A2/fr
Publication of WO2005082892A3 publication Critical patent/WO2005082892A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention a trait à de nouveaux composés de triazole de formule (I), dans laquelle tous les symboles sont tels que définis dans la description, leurs sels pharmaceutiquement acceptables, leurs stéréoisomères, leurs prodrogues, leurs rotamères, les compositions pharmaceutiques les contenant. La présente invention a également trait à un procédé pour la préparation de desdits nouveaux composés.
PCT/IB2005/000343 2004-02-17 2005-02-11 Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant WO2005082892A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN120/CHE/2004 2004-02-17
IN120CH2004 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005082892A2 WO2005082892A2 (fr) 2005-09-09
WO2005082892A3 true WO2005082892A3 (fr) 2006-03-23

Family

ID=34897727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000343 WO2005082892A2 (fr) 2004-02-17 2005-02-11 Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant

Country Status (1)

Country Link
WO (1) WO2005082892A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US20100075984A1 (en) * 2006-01-19 2010-03-25 Laboratorios Salvat, S.A. Dicarbonylic compounds with antibacterial activity
US7763608B2 (en) 2006-05-05 2010-07-27 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
US8742120B2 (en) 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (fr) 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
AR102094A1 (es) * 2014-09-25 2017-02-01 Araxes Pharma Llc Inhibidores de proteínas kras con una mutación g12c
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EP3283462B1 (fr) 2015-04-15 2020-12-02 Araxes Pharma LLC Inhibiteurs tricycliques condensés de kras et procédés pour les utiliser
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058902A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (fr) 2016-03-30 2017-10-05 Araxes Pharma Llc Composés quinazoline substitués et procédés d'utilisation
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
EP3523289A1 (fr) 2016-10-07 2019-08-14 Araxes Pharma LLC Composés hétérocycliques en tant qu'inhibiteurs de ras et leurs procédés d'utilisation
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
WO2018140600A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
WO2018218069A1 (fr) 2017-05-25 2018-11-29 Araxes Pharma Llc Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
EP3630746A1 (fr) 2017-05-25 2020-04-08 Araxes Pharma LLC Composés et leurs procédés d'utilisation pour le traitement du cancer
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (fr) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Pheniloxazolidinones presentant une liaison c-c avec des structures heterocycliques a 4-8 elements
WO1997030995A1 (fr) * 1996-02-24 1997-08-28 Zeneca Limited Derives antibiotiques d'oxazolidinone
WO2001040222A1 (fr) * 1999-12-03 2001-06-07 Astrazeneca Ab Isoxazolines substituees et leur utilisation comme agents antibacteriens
WO2003008395A1 (fr) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles substitues et utilisation comme antibiotiques
WO2003059894A1 (fr) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Nouveaux composes antibacteriens, procede pour leur preparation et compositions pharmaceutiques contenant de tels composes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009328A1 (fr) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Pheniloxazolidinones presentant une liaison c-c avec des structures heterocycliques a 4-8 elements
WO1997030995A1 (fr) * 1996-02-24 1997-08-28 Zeneca Limited Derives antibiotiques d'oxazolidinone
WO2001040222A1 (fr) * 1999-12-03 2001-06-07 Astrazeneca Ab Isoxazolines substituees et leur utilisation comme agents antibacteriens
WO2003008395A1 (fr) * 2001-07-20 2003-01-30 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles substitues et utilisation comme antibiotiques
WO2003059894A1 (fr) * 2002-01-18 2003-07-24 Dr.Reddy's Laboratories Ltd. Nouveaux composes antibacteriens, procede pour leur preparation et compositions pharmaceutiques contenant de tels composes

Also Published As

Publication number Publication date
WO2005082892A2 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2005082892A3 (fr) Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant
CA2499330A1 (fr) Nouvelles quinazolinones spiro-condensees et utilisation associee en tant qu'inhibiteurs de phosphodiesterase
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
WO2004062601A3 (fr) Agents antibacteriens
WO2006087543A8 (fr) Composés antibactériens dérivés de pipéridine
WO2007120647A3 (fr) Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
WO2006067614A3 (fr) Derives heteroaromatiques utiles en tant qu'agents anticancereux
TW200716121A (en) Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists
CA2510853A1 (fr) Derives de pyrrolopyrimidine
WO2004062613A3 (fr) Inhibiteurs d'integrase hiv
TW200616995A (en) Novel compounds
WO2006114520A3 (fr) Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
TW200643013A (en) Pyrazoles
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
WO2006077025A3 (fr) Morpholines en tant qu'agonistes de 5ht2c
WO2004096800A3 (fr) Composes organiques
WO2009082134A3 (fr) Composés inhibiteurs de la dipeptidyl peptidase-4, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
WO2007034279A3 (fr) Antagonistes de c3a et leurs compositions pharmaceutiques
MY150497A (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
WO2007017728A3 (fr) Nouveaux composes heterocycliques
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200639156A (en) New compounds
WO2008006795A3 (fr) Composés d'indole
WO2005040171A8 (fr) Derives de pyrazolo-pyrimidine et d'imidazo-pyrimidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase